Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0944 • ACR Convergence 2021
A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease
Julia Manasson¹, Matthew Stapylton², Rhina Medina¹, Rochelle Castillo³, Parvathy Vasudevanpillai Girija¹, Adriana Heguy¹, Carles Ubeda⁴, Mid-Atlantic Twin Registry (MATR)⁵, Jose Clemente² and Jose Scher¹, ¹New York University School of Medicine, New York, NY, ²Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, ³NYU Langone Health, New York, NY, ⁴La Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain; CIBERESP, Madrid, Spain, ⁵Virginia Commonwealth University, Richmond, VA
Background/Purpose: Psoriasis (PsO) is an inflammatory, immune-mediated skin disorder affecting ~3% of the population worldwide. It is associated with multiple comorbidities, including psoriatic arthritis (PsA),…
Abstract Number: 1319 • ACR Convergence 2021
Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
Natalia Guajardo-Jauregui, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Alejandra Rodriguez-Romero, Diana Flores-Alvarado, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Octavio Ilizaliturri-Guerra, Gisela Garcia-Arellano and Jessica Castillo-Treviño, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have a higher risk of developing a cardiovascular (CV) event than the general population. This could be attributed to…
Abstract Number: 1338 • ACR Convergence 2021
Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
Philip Mease¹, Atul Deodhar², Joseph Merola³, Iain McInnes⁴, Deepak Assudani⁵, Rajan Bajracharya⁵, Jason Coarse⁶, Barbara Ink⁷ and Georg Schett⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Celltech, Slough, UK, Slough, United Kingdom, ⁸Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin outcomes…
Abstract Number: 1355 • ACR Convergence 2021
Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study
Iftach Sagy¹, Yael Shalev Rosenthal², Naama Schwartz² and Lev Pavlovsky², ¹Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ²Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: The objective of this study was to investigate the effect of biological treatments for psoriasis on the incidence of psoriatic arthritis.Methods: A retrospective cohort…
Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Annika Boas⁶ and Hans-Peter Tony⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Abstract Number: 1790 • ACR Convergence 2021
Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study
Haruki Sawada¹, Mitsumasa Kishimoto², Kurisu Tada¹, Gautam Deshpande³, Daiki Kobayashi⁴, Keisuke Ono⁵, Yoshinori Taniguchi⁶, Ayako Hirata⁷, Hideto Kameda⁷, Shigeyoshi Tsuji⁸, Yuko Kaneko⁹, Tadashi Okano¹⁰, Yoichiro Haji¹¹, Hiroaki Dobashi¹², Akimichi Morita¹³, Akihiko Asahina¹⁴, Masato Okada¹⁵, Tetsuya Tomita¹⁶, Diego Benavent¹⁷, Chamaida Plasencia-Rodríguez¹⁸, Victoria Navarro-Compán¹⁷, Clementina López Medina¹⁹, Anna Molto²⁰, Désirée van der Heijde²¹, Maxime Dougados²² and Naoto Tamura¹, ¹Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ²Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ³Department of General Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁶Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Nankoku, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁸Department of Orthopedics and Rheumatology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ¹¹Department of Rheumatology, Daido Hospital, Nagoya, Japan, ¹²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ¹³Department of Geriatric and Environmental Dermatology, Nagoya City University, Nagoya, Japan, ¹⁴Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ¹⁵Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ¹⁶Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁷Rheumatology service, Hospital Universitario La Paz-IdiPaz, madrid, Spain, ¹⁸Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ¹⁹Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ²⁰Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ²¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France
Background/Purpose: Psoriatic arthritis (PsA) shares genetic and clinical features with other forms of spondyloarthritis (SpA). However, no studies have evaluated regional differences regarding characteristics of…
Abstract Number: 1807 • ACR Convergence 2021
Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)
Proton Rahman¹, Philip Mease², Atul Deodhar³, Laure Gossec⁴, Arthur Kavanaugh⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Yan Liu⁸, Xiwu Lin⁸, May Shawi⁹ and Chenglong Han⁸, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³Oregon Health & Science University, Portland, OR, ⁴Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁵University of California San Diego, La Jolla, CA, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada
Background/Purpose: Fatigue is a key patient (pt)-reported symptom of psoriatic arthritis (PsA).1,2 Utilizing data from the Phase 3 DISCOVER-1 (D1) and -2 (D2) studies, these…
Abstract Number: 1825 • ACR Convergence 2021
Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies
Alexis Ogdie¹, Dafna Gladman², Laura Coates³, Effie Pournara⁴, Xiangyi Meng⁵, Bhumik Parikh⁵ and Philip Mease⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Oligoarticular psoriatic arthritis (PsA), defined as involvement of ≤ 4 joints, affects approximately 50% of the PsA population.1,2 Disease burden is comparable for patients…
Abstract Number: PP02 • ACR Convergence 2021
Leveraging Digital Health Tracking to Improve Arthritis Management
Katie Roberts, Annapolis, MD
Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
Abstract Number: 0140 • ACR Convergence 2021
Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis
Jana Ziob¹, Charlotte Behning¹, Peter Brossart², Thomas Bieber¹, Dagmar Wilsmann-Theis³ and Valentin Schäfer⁴, ¹University Hospital Bonn, Bonn, Germany, ²Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany
Background/Purpose: An interdisciplinary approach involving dermatologists and rheumatologists is required for the management of patients with psoriatic arthritis (PsA). The purpose of our study was…
Abstract Number: 0565 • ACR Convergence 2021
Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety
Brian Breviu¹, Shaobo Pei¹, Matthew Kirkpatrick², Bingjian Feng¹ and Jessica Walsh³, ¹Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Depression and anxiety are common in patients with inflammatory arthritis (IA), and have been reported as risk factors for various inflammatory diseases. The study…
Abstract Number: 0946 • ACR Convergence 2021
Distinct Lipidomic Signatures in Synovium and Synovial Fluid of Patients with Rheumatoid Arthritis versus Psoriatic Arthritis
Beatriz Rocha¹, Berta Cillero-Pastor², Anna Illiano³, Valentina Calamia¹, Gabriella Pinto⁴, Angela Amoresano⁴, Cristina Ruiz-Romero⁵, Juan D Cañete⁶, Ron MA Heeren² and Francisco Blanco-García⁷, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006 A Coruña, España., A Coruña, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands., Maastricht, Netherlands, ³CEINGE - Advanced Biotecnology, 80145 Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy., Naples, Italy, ⁴Department of Chemical Sciences, University of Naples “Federico II”, Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy, ⁵Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain, ⁷Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The differential diagnosis of Rheumatoid Arthritis (RA) and Psoriatic arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of…
Abstract Number: 1321 • ACR Convergence 2021
Uveitis in Patients with Psoriatic Arthritis – a Database Analysis
Nizar Hijaze¹, Tal Gazitt², Amir Haddad³, Muna Elias⁴, Idit Lavi⁴, Ilan Feldhamer⁵, Arnon Dov Cohen⁵, Shaul Sar⁴, Oren Tomkins Netzr⁴ and Devy Zisman⁴, ¹Carmel medical centre, Tamra, Israel, ²Carmel Hospital, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Clalit Health Services, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) belongs to the group of spondyloarthropathies in which uveitis is an associated disease . The prevalence of uveitis among PsA patients…
Abstract Number: 1339 • ACR Convergence 2021
Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study
Laure Gossec¹, Stefan Siebert², Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz Joven-Ibáñez⁶, Tatiana Korotaeva⁷, Wim Noël⁸, Michael Nurmohamed⁹, Petros Sfikakis¹⁰, Elke Theander¹¹ and Josef Smolen¹², ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²University of Glasgow, Glasgow, United Kingdom, ³Janssen-Cilag BV, Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁹Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ¹⁰National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹¹Janssen Cilag, Lund, Sweden, ¹²Medical University of Vienna, Vienna, Austria
Background/Purpose: Several options exist in the treatment of PsA, but data on long-term persistence are rare. Here, we assess long-term persistence with ustekinumab (UST) or…
Abstract Number: 1356 • ACR Convergence 2021
Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis
Ashley Elliott¹, Gary Wright², Adrian Pendleton² and Madeleine Rooney¹, ¹Centre for Experimental Medicine , School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, UK, Belfast, Northern Ireland, United Kingdom, ²Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Enthesitis is an important aspect of disease in PsA and its clinical assessment has problems in terms of sensitivity and overlap with alternative co-morbid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].